HROWM - Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025
2025-03-01 08:50:08 ET
Summary
- Harrow Health's robust distribution platform and patented eye care products create a strong moat, offering an attractive entry point after the recent stock price correction.
- Catalysts in 2025 could come from a successful Triesence launch and potential NDA filing for Melt pharma, where HROW has a material stake.
- The main risk is the company's loss in Q3 2024 despite recent acquisitions, so more revenue growth alongside controlled costs is needed for the stock to work from here.
- With good progress on Triesence and Melt's NDA filing, it's possible the stock could double to around $55/share in 2025.
- Nonetheless, without anticipated progress on these two major catalysts, the current $27/share valuation would be at risk.
Harrow Health ( HROW ) is a founder-led eye health company with a roughly $1B market capitalization that has seen strong growth in recent years due to savvy acquisitions. The stock got a little ahead of itself in 2024 and operational issues for Q3 caused the shares to fall back to what is likely now an attractive entry point....
Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025